Business Investment Opportunities

Looking for strategic investors in the US/UK market that can help us expand. - We are a leading healthcare specialised digital marketing firm that provides end-to-end services to healthcare clients. - Currently catering to leading healthcare brands. - Offer a specialized approach to our clients that leverages social media, paid search, search engine optimization and other such avenues. - Large part of the business is through client retainers. high client retention has been the key differentiator for the brand. Working with brands such as Astra Zeneca, Roche, Emcure, Glenmark and Emami. - Strong promoter pedigree with experience across management consulting, marketing enterprise planning and end to end digital marketing. - Business has high growth potential and we seek a strategic acquisition to help tap into additional clients and expand the business.

Business owner of a drug wholesale business planning to establish a pharmaceutical drug manufacturing plant. - The focus will be on creating a portfolio of drugs under the company's own brand name. - Initially, the manufacturing will concentrate on oral tablets and capsules, with future plans for expansion into other drug categories. - The company aims to supply its products to distributors across West Bengal, Jharkhand, Bihar, and Odisha. - Raw materials for the manufacturing process will be sourced from Ahmedabad and Visakhapatnam. - Will be obtaining drug license and FDA approval once the business launches.

An AI-enhanced physics-based drug discovery company. - Integrates artificial intelligence, computational chemistry, and peptide science to expedite therapeutic compound discovery and optimize leads. - Discovers and optimizes active, specific, non-toxic, and patentable small molecules delivering superior drug candidates. - The company boasts a diverse clientele, with more than 6 clients including reputable organizations such as Deloitte Belgium, B. Braun, Fresenius Kabi, and UCB Pharma. - The company currently generates revenue through the provision of management consulting services for pharmaceutical and biotech companies. It operates on a per-service-based charging model. - Company is currently engaged in the development of brain-specific and selective butyrylcholinesterase inhibitors for the treatment of severe Alzheimer's. - The business is not yet profitable as it is reinvesting its revenue into research and development activities, - The company has 2 additional contract employees for R&D activities.

An AI-enhanced physics-based drug discovery company. - Integrates artificial intelligence, computational chemistry, and peptide science to expedite therapeutic compound discovery and optimize leads. - Discovers and optimizes active, specific, non-toxic, and patentable small molecules delivering superior drug candidates. - The company boasts a diverse clientele, with more than 6 clients including reputable organizations such as Deloitte Belgium, B. Braun, Fresenius Kabi, and UCB Pharma. - The company currently generates revenue through the provision of management consulting services for pharmaceutical and biotech companies. It operates on a per-service-based charging model. - Company is currently engaged in the development of brain-specific and selective butyrylcholinesterase inhibitors for the treatment of severe Alzheimer's. - The business is not yet profitable as it is reinvesting its revenue into research and development activities, - The company has 2 additional contract employees for R&D activities.

We are a manufacturer of precision plastic injection molds and parts. - Some of the sectors that we work for are FMCG, pharma, medical and engineering. - We have 15 clients and they include major names like Unilever, Mundi Pharma and Dynaplast. - Have all the precision quality control tools in place like height gauges, micrometers and precision gauges. - All our employees are highly experienced and fully trained to carry out the operations.

High potential company with a science-proven, patented beverage for acute alcohol intoxication. - Our product is a science-based beverage designed for the resolution of acute alcohol toxicity. - The company has developed this product over the past 3 years and is now seeking early-stage investors to bring it to market. - We are in discussions with approximately 18 major clients in the pharmaceutical industry, including pharma product buyers and large pharmacies such as Audifarma and Eticos Serrano, to ensure effective product introduction and distribution. - Our team has over 4 years of successful experience in launching pharmaceutical products in the Colombian market. - We will be available in the market in the next few months. - Our target audience is the alcohol consumption market, focusing on providing a solution for alcohol elimination in intoxicated individuals. - The company is currently in the pre-seed stage. - We are planning to establish a manufacturing unit soon, with a production capacity of 100,000 units per month. - Company has incorporation license and INVIMA registration (license from the National Food and Drug Surveillance Institute)

The business offers a wide range of customized food processing machines for primary handling & processing. - Our clients are small food businesses, pharma companies, NGOs, and government-funded programs. - Currently, we have around 150 clients. - The business is growing at the rate of 400% YOY in terms of revenue. This is because we have adopted a new technology that makes our production process efficient. - We generate revenue by selling machines & spare parts. - The manufacturing is outsourced and we have tie-ups with 15-16 such vendors. - Products are sold under our own brand name & are manufactured using our designs. - The finished products are then tested by us in our facility and then delivered to the client's facility. - We assemble the machines at the client's premises. - The business has two partners with a 60% and a 40% stake in the company. - The company does not have any outstanding loans.

The company primarily sells handmade herbal soap and facewash which makes up about 70-80% of revenue. - In addition to its own products, the company also serves as a distributor for liver tonic and iron tonic products from established pharma companies Cura and New Salasar, offering a diversified revenue stream. - The promoter has previous experience in a senior divisional manager role in a well-known pharma company, bringing industry expertise to the business. - The company currently operates within Bihar and Patna, with its products available in 100 stores and sold through doctors, presenting an opportunity for geographical expansion. - Manufacturing is outsourced to two third-party manufacturers, and the company is in the process of listing its products on Amazon to tap into the online market. - The business was started towards the last few months of 2023 and hence has no reported sales. - The company has a high valuation expectation due to the anticipated future growth prospects due to the high demand of products in the market and untapped potential offered due to a lack of marketing and online sales currently. The expansion will be driven by increasing product range and market reach, including potential listing on online platforms like Amazon to increase the value of the company.

Upcoming medtech startup that will cater to the clinical trials market. - Poland is emerging as a significant hub for clinical research in Europe, particularly for phase 3 trials across therapeutic areas like oncology, cardiology, dermatology, and neurology. - Major cities like Warsaw and Krakow are key locations for conducting these trials due to their high patient recruitment rates and quality research facilities. - Sponsors are attracted to Poland's harmonized regulatory environment, efficient research sites, and large patient pool, making it a compelling destination for global clinical trials. - Our app will cater to the entire ecosystem of clinical trials and create a system wherein labs and sponsors can easily maintain records and communicate with patients. - We have not finalized a revenue model but the labs, and sponsors will be our paying customers. - We are in the incubation phase and our expected revenues within two years is approx. PLN 1-2 million. - Owner's background: PM software development for international companies from the pharma, healthcare, news media, banking industries.

•⁠ ⁠The technology is employed by over 200 prominent companies globally. •⁠ ⁠Our company holds exclusive rights in strategically vital regions worldwide. •⁠ ⁠In these regions, we have a robust presence, ongoing pilot agreements, and over 20 negotiations with market leaders in fields such as insurance, healthcare, pharma, and more. •⁠ ⁠As a newly established startup, our revenue is projected to commence in the second quarter of this year. •⁠ ⁠The founders boast nearly two decades of experience in startup leadership and executive roles within multinational companies, fostering strong business relationships in the primary region of our operations. • Our aim is to be the first AI healthcare aggregator platform, offering 360 health monitoring through an SDK/API connected to users' phones. This adaptable solution enables our B2B clients to integrate our SDK/API into their apps, aligning with their distinct business models. The delivery of hyper-personalized goods and services can be facilitated either through us or directly through the B2B client, depending on their specific needs and preferences. • We possess medical licenses, partial FDA approval and CE approval. • Currently we have our operations in Russia and Georgia.

Ayurvedic products marketing company being operated by 4 partners. - We have 13-14 products now and in the process to add 7-8 new products next month. - All the products are manufactured under our own brand name by a third party manufacturer based in Secunderabad. - We plan to set-up our own manufacturing facility in Kochi by next year. - We have over 3,000 doctors on our network. - The company focuses on a policy of direct selling to stocking doctors as well as prescription sales through distributors. The percentage of direct sales is as high as 70% compared to prescription sales of 30%. - The medicines are generic in nature without chemical ingredients. - Medicines are patented and trademarked. All are approved by the concerned authorities (AYUSH certified). - First-month revenue was INR 50K and the latest month revenue was INR 8-9 lakhs. Projected monthly sales for the next year is INR 25 lakhs. - Business was started 2 years ago as a partnership entity and recently converted the legal entity to a private limited. - Each promoter has more than 15 years of experience in different fields such as pharma, business management, finance, HR.